Image credit: acn newswire
PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, has nnounced a new milestone in the manufacturing of IndoVac, a COVID-19 vaccine brand it has developed since November 2021.
The company collaborated with Baylor College of Medicine, a private, independent health sciences centre in Houston, Texas to develop IndoVac, a recombinant protein subunit vaccine produced from yeast.
PT Bio Farma has completed Phase 1 and Phase 2 clinical trials and is currently in the Phase 3 stage to produce the primary series vaccines or two vaccine doses for everyone aged 18 years and older. The company has also started clinical trials for its booster vaccine. Next, Bio Farma plans to conduct clinical trials for children.
Indonesian Food and Drug Authority head Penny K. Lukito, during a hearing with Commission IX at the Indonesian House of Representatives, has said that the regulator expects to release the emergency use authorisation (EUA) for IndoVac's primary series vaccines in mid-September 2022.
